Ligand Pharmaceuticals/$LGND
1D1W1MYTD1Y5YMAX
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
- Ticker
- $LGND
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 47
- Headquarters
- Jupiter, United States
- Website
- www.ligand.com
LGND Metrics
BasicAdvanced
$5.7B
30.92
$9.19
0.98
-
Price and volume
Market cap
$5.7B
Beta
0.98
52-week high
$326.63
52-week low
$160.80
Average daily volume
247K
Financial strength
Current ratio
34.521
Quick ratio
34.521
Long term debt to equity
116.832
Total debt to equity
116.442
Interest coverage (TTM)
21.23%
Profitability
EBITDA (TTM)
133.011
Gross margin (TTM)
81.20%
Net profit margin (TTM)
67.88%
Operating margin (TTM)
34.45%
Effective tax rate (TTM)
17.12%
Revenue per employee (TTM)
$6,180,000
Management effectiveness
Return on assets (TTM)
3.99%
Return on equity (TTM)
21.96%
Valuation
Price to earnings (TTM)
30.923
Price to revenue (TTM)
19.27
Price to book
5.85
Price to tangible book (TTM)
8.68
Price to free cash flow (TTM)
42.597
Free cash flow yield (TTM)
2.35%
Free cash flow per share (TTM)
6.673
Growth
Revenue change (TTM)
54.89%
Earnings per share change (TTM)
-329.98%
3-year revenue growth (CAGR)
17.32%
10-year revenue growth (CAGR)
12.68%
3-year earnings per share growth (CAGR)
80.56%
10-year earnings per share growth (CAGR)
-0.59%
What the Analysts think about LGND
Analyst ratings (Buy, Hold, Sell) for Ligand Pharmaceuticals stock.
LGND Financial Performance
Revenues and expenses
LGND Earnings Performance
Company profitability
LGND News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.